March 4, 2009 / 5:01 PM / 11 years ago

Glaxo seeks EU approval for kidney cancer drug

LONDON, March 4 (Reuters) - GlaxoSmithKline (GSK.L) said on Wednesday it had submitted its experimental kidney cancer drug pazopanib for approval in Europe.

The drug, which is given by mouth, is designed for patients with advanced or metastatic kidney cancer.

The filing with the European Medicines Agency follows a similar submission to the U.S. Food and Drug Administration in December. (Reporting by Ben Hirschler)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below